Navigation Links
EGEN, Inc. Announces that Phase II Clinical Trial for Advanced Ovarian Cancer is Open for Enrollment
Date:12/13/2010

HUNTSVILLE, Ala., Dec. 13, 2010 /PRNewswire/ -- EGEN, Inc. today announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment.  The trial is sponsored by the Gynecologic Oncology Group (GOG) under an agreement between the GOG and EGEN, Inc., and is being conducted by a network of researchers led by the GOG at member institutions.  The University of Alabama at Birmingham (UAB) Hospital is the first member institution to open enrollment. Dr. Ronald Alvarez, of UAB Hospital, is the Study Chair for the trial. The GOG Principal Investigator at UAB Hospital is Dr. Mack Barnes.  

"This is a significant milestone and accomplishment for the company," commented Dr. Khursheed Anwer, President and CSO of EGEN. "We are pleased to have this trial begin as it advances our novel EGEN-001 product in the clinic for the treatment of recurrent ovarian cancer.  The product utilizes the Company's proprietary TheraPlas® delivery technology and is composed of interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 is a potent cytokine which works by enhancing the body's immune system against cancer and inhibiting tumor blood supply.  We expect a number of the leading cancer centers in the U.S. to participate in this study and planning is underway to initiate additional Phase II trials in 2011, including the evaluation of EGEN-001 in treatment of colorectal cancer patients."

About Ovarian Cancer

Ovarian cancer represents the fifth most common form of cancer affecting women and is the most lethal of gynecological malignancies, ranking fourth in cancer deaths among women. The death rate for this disease has not changed much in the last 50 years.  This cancer is often diagnosed at an advanced stage after the cancer has spread beyond the ovary. Over $2 billion is spent in the U. S. each year on treatment of ovarian cancer.<
'/>"/>

SOURCE EGEN, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 2014 Kush Bottles, North America,s ... and consulting services for the medical and recreational marijuana ... has assumed the role of Chief Executive Officer. ... and worked as COO until February of 2014, returned ... other ventures. His return marks a clear dedication to ...
(Date:9/29/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today announced that its Qionglai Facility (QLF) has ... China Food & Drug Administration,s (CFDA) for its ... early September 2014, the Company has submitted the ...
(Date:9/29/2014)... and CAMBRIDGE, Mass. ... Solutions and KEW Group, Inc. (KEW), a privately ... for the two companies to make KEW,s state-of-the-art ... customers. KEW is a privately held ... cancer care by empowering all oncologists to access ...
Breaking Medicine Technology:Kush Bottles Co-Founder Steps into Role of CEO 2TPI's QLF Completes GMP site inspection by CFDA 2TPI's QLF Completes GMP site inspection by CFDA 3Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 2Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 3Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 4
... Oslo Cancer Cluster represents a strong R&D environment dedicated ... lies within developing novel technologies and significantly better cancer ... Oslo Cancer Cluster is a research and ... accelerating the development of new cancer diagnostics and medicines. ...
... 31, 2011 Menicon Holdings BV and Eye Shelter ... France-based independent ophthalmic group, announced on October 31 that ... market the SOLO-care (R) contact lens solutions range in ... The agreement will enable Menicon to significantly ...
Cached Medicine Technology:Expanding Norwegian Cluster of Excellence Dedicated to Oncology 2Expanding Norwegian Cluster of Excellence Dedicated to Oncology 3Menicon to Market Eye Shelter's SOLO-care (R) Contact Lens Solution Range in Europe and Canada 2
(Date:9/29/2014)... (PRWEB) September 30, 2014 NAPW ... Clinical Manager Specialist, as a 2014 Professional Woman of ... distinction for leadership in clinical care. As the largest ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
(Date:9/29/2014)... Every autumn, as high school and college gets ... takes off! Athletes typically train throughout the summer in ... the leading compression apparel company, makes the best ... for cross country running. , The compression leg ... muscle soreness (DOMS) throughout training in addition to speeding ...
(Date:9/29/2014)... 2014 China’s regulatory framework for ... country’s new leaders have recognized that the regulations ... are far from perfect along with rapid population ... years. Chinese state council issued the latest “Regulations ... on February 12, 2014, and it has come ...
(Date:9/29/2014)... (PRWEB) September 29, 2014 Leading Conejo ... (PMIR) and Thousand Oaks Surgery Center (TOSC) –– are ... a state-of-the-art healthcare facility in Thousand Oaks, Calif. The ... practices that offer Conejo Valley residents greater access to ... and chronic pain, while TOSC physicians are setting the ...
(Date:9/29/2014)... The Pulmonary Hypertension Association ... Centers (PHCC) in a program that seeks to ... of patients with pulmonary hypertension (PH), specifically pulmonary arterial ... the lungs that affects the functioning of the heart ... mean survivability is only 2.8 years. , Despite medical ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Sarah Shiermeister, Clinical Manager Specialist at Gentiva Health Services, a 2014 Professional Woman of the Year 2Health News:Muscle Support and Style With New Compression Leg Sleeves For Cross Country Runners 2Health News:Chinese Regulations on In-Vitro Diagnostic Reagents Market: Application & Approval 2014 Edition New Study Now Available at MarketReportsOnline.com 2Health News:Chinese Regulations on In-Vitro Diagnostic Reagents Market: Application & Approval 2014 Edition New Study Now Available at MarketReportsOnline.com 3Health News:Chinese Regulations on In-Vitro Diagnostic Reagents Market: Application & Approval 2014 Edition New Study Now Available at MarketReportsOnline.com 4Health News:New Thousand Oaks Medical Facility Hosts Grand Opening Event: Two Practices, One Celebration 2Health News:New Thousand Oaks Medical Facility Hosts Grand Opening Event: Two Practices, One Celebration 3Health News:Pulmonary Hypertension Association Accredits First Six PH Care CentersApplication Process Now Open 2Health News:Pulmonary Hypertension Association Accredits First Six PH Care CentersApplication Process Now Open 3Health News:Pulmonary Hypertension Association Accredits First Six PH Care CentersApplication Process Now Open 4
... Society for Technology in Anesthesia Annual Meeting Quantifies ... Improved ICU UtilizationIRVINE, Calif., Jan. 20 Masimo ... Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion ... clinicians at Dartmouth-Hitchcock Medical Center (DHMC) presented new ...
... its 2008 distributions as follows:, Security Description: Common Stock, ... Ticker Symbol: BMR, ... Total ... Ordinary, Date Date ...
... clients in these tough economic times. , ... Wayne, NJ (PRWEB) January ... being hit hard. To succeed, CMS, a leader in the staffing ... moves such as utilizing the temporary workforce. , ,By ...
... 19 Anyone who has gone through,finding a long-term ... is,to search for and find a care facility such ... know how senior living can be expensive and stressful,trying ... and meets the,financial demands of senior citizens without knowing ...
... operation differ about 20% of the time, researchers say ... severe osteoarthritis tend to be happier with their care ... providers on the issue of total knee replacement, a ... patients don,t agree with providers when it comes to ...
... recommended care did better, regardless of race, study found ... between white and black patients with early-stage lung cancer ... a U.S. study that included nearly 18,000 patients. ... (pulmonary resection) provides the best chance of a cure ...
Cached Medicine News:Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 2Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 3Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 4Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 5Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 6Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 7Health News:BioMed Realty Trust Announces Tax Treatment of 2008 Distributions 2Health News:BioMed Realty Trust Announces Tax Treatment of 2008 Distributions 3Health News:CMS Staffing Announces a its New and Revolutionary Consultative Approach With Clients 2Health News:Raising the Quality of Long-Term Care for Seniors 2Health News:Raising the Quality of Long-Term Care for Seniors 3Health News:Knee Replacement Works Best When Patients, Providers Agree 2Health News:Optimal Treatment Boosts Blacks' Lung Cancer Survival 2
The 6.5mm cannulated cancellous ACE SCFE Screw is specifically designed for the treatment of slipped capital femoral epiphysis. The ACE SCFE Screw simplifies insertion and facilitates removal....
Smith & Nephew offers a wide variety of cannulated screw products. Most screw sizes are available in both partially threaded and fully threaded versions. , ,All systems optimize implant strength with...
... Humeral Nail enables fixation of humeral shaft ... may be associated with antegrade nailing. , ... distal interlocking using a nail-mounted targeting device. ... with the patient in the prone position. ...
... leading medical technology company and a ... more than a decade, introduces a ... ACT Plus System is a microprocessor-controlled ... coagulation endpoints in whole blood, citrated ...
Medicine Products: